UK’s NICE Says No To AstraZeneca’s Evusheld Amid ‘Rapidly Changing’ COVID-19 landscape
Executive Summary
NICE says that limitations in the evidence for Evusheld make it difficult to produce a reliable cost-effectiveness estimate.
You may also be interested in...
Three COVID-19 Drugs Clear UK Funding Hurdle But Olumiant No Longer In The Running
NICE says it is the first health technology assessment body to look at the non-pandemic use of COVID-19 treatments. It is also planning to launch a consultation on a new process for updating its recommendations on such products with a view to making them available more quickly if new variants emerge.
AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.